From: Clinicopathological characteristics of patients with paraproteinemia and renal damage
 | MGRS (n  =  42) | MM (n  =  14) | MGUS (n  =  19) | Renal monoIg (n  =  21) | P value |
---|---|---|---|---|---|
Special treatment [n (%)] | 36 (85.7) | 13 (92.9) | 13 (68.4) | 18 (85.7) | 0.239 |
Chemotherapy [n (%)] | 19 (45.2)a,b,c | 12 (85.7)d,e | 0 (0) | 0 (0) | 0.000 |
Immunosuppression [n (%)] | 12 (28.6)a,b,c | 0 (0)d,e | 12 (63.2) | 18 (85.7) | 0.000 |
Follow-up time (months) | 47.6  ±  19.2 | 50.9  ±  18.4 | 38.9  ±  14.7 | 40.4  ±  10.0 | 0.080 |
Major response [n (%)] | 10 (23.8)a,b,c | 0 (0)d,e | 11 (57.9)f | 18 (85.7) | 0.000 |
Partial response [n (%)] | 16 (38.1) | 6 (42.9) | 5 (26.3) | 3 (14.3) | 0.185 |
ESRD [n (%)] | 14 (33.3)b | 8 (57.1)d,e | 1(5.3) | 0 (0) | 0.025 |
Baseline eGFR (mL/min) | 50.0 (14.7, 89.0) | 15.6 (5.8, 34.7) | 22 | – | 0.732 |
Renal survival time (months) | 8.8  ±  10.0 | 9  ±  16.6 | 2 | – | 0.507 |
Death [n (%)] | 7 (16.7)b,c | 3 (21.4)d,e | 0 (0) | 0 (0) | 0.014 |
Survival time (months) | 9.4  ±  8.4 | 8.0  ±  6.1 | – | – | 0.651 |